These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 7572928)

  • 1. Low prevalence of Helicobacter pylori in inflammatory bowel disease: association with sulfasalazine.
    Mantzaris GJ; Archavlis E; Zografos C; Zavos K; Petraki K; Triadaphyllou G
    Am J Gastroenterol; 1995 Oct; 90(10):1900. PubMed ID: 7572928
    [No Abstract]   [Full Text] [Related]  

  • 2. [Helicobacter pylori and nonspecific intestinal inflammation].
    Münzová H; Dítĕ P; Sevcíková I; Dolina J; Novotný I; Kunovská M
    Vnitr Lek; 2000 Dec; 46(12):839-42. PubMed ID: 11214362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lower prevalence of Helicobacter pylori infection in patients with inflammatory bowel disease but not with chronic obstructive pulmonary disease - antibiotic use in the history does not play a significant role.
    Prónai L; Schandl L; Orosz Z; Magyar P; Tulassay Z
    Helicobacter; 2004 Jun; 9(3):278-83. PubMed ID: 15165265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does Helicobacter pylori play a role in inflammatory bowel disease?
    Nardone G; Rocco A; Budillon G
    Ital J Gastroenterol Hepatol; 1998 Feb; 30(1):134-7. PubMed ID: 9615282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of the prevalence of infection with Helicobacter pylori in patients with inflammatory bowel disease.
    Pearce CB; Duncan HD; Timmis L; Green JR
    Eur J Gastroenterol Hepatol; 2000 Apr; 12(4):439-43. PubMed ID: 10783998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse effects of sulfasalazine and treatment of ulcerative colitis with mesalazine.
    Nakajima H; Munakata A; Yoshida Y
    J Gastroenterol; 1995 Nov; 30 Suppl 8():115-7. PubMed ID: 8563870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Diffuse proliferative lupus nephritis in a patient with ulcerative colitis].
    Sugiyama T; Oishi Y; Sueishi M; Matsumura R; Tomioka H; Akikusa B
    Ryumachi; 1996 Aug; 36(4):651-5. PubMed ID: 8911083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trends in the prevalence of peptic ulcer disease and Helicobacter pylori infection in family physician-referred uninvestigated dyspeptic patients in Hong Kong.
    Xia B; Xia HH; Ma CW; Wong KW; Fung FM; Hui CK; Chan CK; Chan AO; Lai KC; Yuen MF; Wong BC
    Aliment Pharmacol Ther; 2005 Aug; 22(3):243-9. PubMed ID: 16091062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Drug treatment of chronic inflammatory diseases of the intestine].
    Modigliani R
    Schweiz Med Wochenschr; 1988 May; 118(20):737. PubMed ID: 2898809
    [No Abstract]   [Full Text] [Related]  

  • 10. Chloroquine for mild to moderately active ulcerative colitis: comparison with sulfasalazine.
    Goenka MK; Kochhar R; Tandia B; Mehta SK
    Am J Gastroenterol; 1996 May; 91(5):917-21. PubMed ID: 8633581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of ulcerative hemorrhaging colitis with immunosuppressive drugs].
    Maleev A; Stoianov S; Sirakov P
    Vutr Boles; 1972; 11(3):123-5. PubMed ID: 4154528
    [No Abstract]   [Full Text] [Related]  

  • 12. [Digestive and extra-digestive complications of nonsteroidal anti-inflammatory drugs. Preventive and curative strategies].
    Sternon J; Adler M
    Rev Med Brux; 1997 Apr; 18(2):52-8. PubMed ID: 9221462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Helicobacter pylori and perforated peptic ulcer prevalence of the infection and role of non-steroidal anti-inflammatory drugs.
    Gisbert JP; Legido J; García-Sanz I; Pajares JM
    Dig Liver Dis; 2004 Feb; 36(2):116-20. PubMed ID: 15002818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of Helicobacter species in chronic liver disease and chronic inflammatory bowel disease.
    Veijola L; Nilsson I; Halme L; Al-Soud WA; Mäkinen J; Ljungh A; Rautelin H
    Ann Med; 2007; 39(7):554-60. PubMed ID: 17852032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low prevalence of Helicobacter pylori in inflammatory bowel disease: association with sulphasalazine.
    el-Omar E; Penman I; Cruikshank G; Dover S; Banerjee S; Williams C; McColl KE
    Gut; 1994 Oct; 35(10):1385-8. PubMed ID: 7959192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prevalence of Helicobacter pylori infection in duodenal ulcer. Data of a prospective study apropos of 78 NSAID-negative patients with duodenal ulcer].
    Ben Ammar A; Cheikh I; Ouerghi H; Chaabouni H; Kchaou M; Ben Mami N
    Tunis Med; 2002 Oct; 80(10):599-604. PubMed ID: 12632753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of sulfasalazine in the treatment of inflammatory bowel disease.
    Spector R
    J Iowa Med Soc; 1983 Jun; 73(6):230-4. PubMed ID: 6135735
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical onset of the Crohn's disease after eradication therapy of Helicobacter pylori infection. Does Helicobacter pylori infection interact with natural history of inflammatory bowel diseases?
    Jovanovic IR; Milosavjevic TN; Jankovic GP; Micev MM; Dugalic PD; Saranovic D; Ugljesic MM; Popovic DV; Bulajic MM
    Med Sci Monit; 2001; 7(1):137-41. PubMed ID: 11208510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chronic inflammatory bowel diseases. Update on evidence-based therapy].
    MMW Fortschr Med; 2005 Apr; 147(17):58-9. PubMed ID: 15903063
    [No Abstract]   [Full Text] [Related]  

  • 20. An unusual complication of immunosuppressive therapy in inflammatory bowel disease.
    Khatchatourian M; Seaton TL
    Am J Gastroenterol; 1997 Sep; 92(9):1558-60. PubMed ID: 9317088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.